CIRCULATING TUMOUR DNA AS A NONINVASIVE BIOMARKER IN MELANOMA
Grant number: 1107126 | Funding period: 2016 - 2020
The expanding repertoire of treatment options in melanoma is bringing into focus the need for improved ways to accurately monitor treatment responses and guide treatment decisions. Many cancers shed small amounts of DNA (ctDNA) into the bloodstream and changes in ctDNA levels have potential to be used as specific markers of response to cancer therapy. This project will evaluate if ctDNA can be used as a form of ‘liquid biopsy’ to guide treatment decisions in patients with melanoma.
Related publications (3)
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
L Tan, S Sandhu, RJ Lee, J Li, J Callahan, S Ftouni, N Dhomen, P Middlehurst, A Wallace, J Raleigh, A Hatzimihalis, MA Henderson, M Shackleton, A Haydon, V Mar, DE Gyorki, D Oudit, MA Dawson, RJ Hicks, P Lorigan
BACKGROUND: The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify pa..
Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes
Paul Yeh, Michael Dickinson, Sarah Ftouni, Tane Hunter, Devbarna Sinha, Stephen Q Wong, Rishu Agarwal, Ravikiran Vedururu, Kenneth Doig, Chun Yew Fong, Piers Blombery, David Westerman, Mark A Dawson, Sarah-Jane Dawson
Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma
Stephen Q Wong, Jeanette M Raleigh, Jason Callahan, Ismael A Vergara, Sarah Ftouni, Athena Hatzimihalis, Andrew J Colebatch, Jason Li, Timothy Semple, Kenneth Doig, Christopher Mintoff, Devbarna Sinha, Paul Yeh, Maria Joao Silva, Kathryn Alsop, Heather Thorne, David D Bowtell, David E Gyorki, Gisela Mir Arnau, Carleen Cullinane